Acute Tubulointerstitial Nephritis Induced by Deferasirox following Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia
Korean Journal of Hematology
;
: 258-262, 2008.
Artigo
em Coreano
| WPRIM
| ID: wpr-720441
ABSTRACT
Deferasirox is a once-daily, oral iron-chelating agent that is now widely available for the treatment of transfusional hemosiderosis. Deferasirox represents a significant advance in the treatment of iron overload, as the availability of an effective oral therapy has the potential to relieve many patients from the burden of frequent parenteral therapy with the previous reference standard iron chelator, deferoxamine. The well-known drug-related adverse events associated with deferasirox include gastrointestinal disturbances, rash, elevations in liver enzyme levels, and mild increases in serum creatinine levels, but acute renal failure is not common. The authors report a case of acute tubulointerstitial nephritis induced by deferasirox following hematopoietic stem cell transplantation for severe aplastic anemia
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Triazóis
/
Benzoatos
/
Células-Tronco Hematopoéticas
/
Transplante de Células-Tronco Hematopoéticas
/
Sobrecarga de Ferro
/
Creatinina
/
Desferroxamina
/
Exantema
/
Injúria Renal Aguda
/
Hemossiderose
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Hematology
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS